Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Gastroesophageal junction carcinoma (GEJ) is a difficult-to-treat malignancy that constitutes a large minority of all gastric cancers. One of the key difficulties in treating the disease is the ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck executive said — and some analysts agree. “I see these results as important, but preliminary,” Merck ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

At the pre-specified interim analysis, Keytruda, combined with SBRT, did not demonstrate an improvement in event-free survival or overall survival, the study's primary endpoint and key secondary ...

EFS and pCR are the KEYNOTE-522 trial’s dual primary endpoints, and overall survival is a key secondary endpoint. In the current analysis, Keytruda’s EFS benefit remained strong, with the drug ...

In MSI-H or dMMR endometrial cancer, Keytruda achieved an objective response rate (ORR) of 46%, including 12% complete responses and 33% partial responses, after a median of 16 months' follow-up.